Central to this paradigm is the concept of drug retention in tumor microenvironments—a critical yet historically underappreciated factor influencing treatment outcomes. While conventional therapies often rely on molecules engineered to home in on tumor-specific markers, the physical dwell time of the drug within malignant tissues is equally pivotal. Insufficient local retention can precipitate rapid drug clearance, diminishing therapeutic impact and expanding systemic toxicity. Addressing this challenge, the newly developed system leverages restricted interaction peptides (RIPs) that undergo conformational shifts upon enzymatic activation, enabling them to insert firmly into cell membranes.

These RIPs are ingeniously programmed to respond selectively to fibroblast activation protein (FAP), a protease overexpressed in the stroma of many solid tumors. Upon enzymatic processing by FAP, the peptides transform structurally, adopting amphiphilic configurations that facilitate membrane insertion and tether the attached therapeutic cargo directly to cancer cell surfaces. This targeted membrane anchoring effectively transforms the drug into a “molecular grappling hook,” securing it precisely where it is most needed and promoting enhanced cellular uptake.

Preclinical evaluations underscore the system’s potential. Fluorescently labeled RIPs exhibited rapid and specific uptake by cultured cancer cells, validating the mechanism of membrane engagement. When conjugated to monomethyl auristatin E, a potent chemotherapeutic, the combined molecule retained cytotoxic efficacy equal to that of the free drug in vitro. Crucially, in vivo studies using murine models implanted with human tumors demonstrated that the RIP-drug conjugate accumulated selectively in tumor tissue. This selective localization translated to superior tumor regression and reduced systemic side effects compared to administering the drug alone.

Expanding the versatility of this platform, researchers substituted the chemotherapeutic payload with radioactive copper isotopes commonly employed in nuclear medicine. This adaptation yielded comparable tumor binding and shrinkage efficacy, effectively establishing a theranostic agent capable of both diagnosing and treating cancers. The dual functionality heralds a new era wherein a single molecular entity can seamlessly traverse the translational gap between imaging and therapy, optimizing personalized cancer management.

The implications of these findings extend beyond the laboratory. Plans are underway to initiate Phase 1 clinical imaging trials using the RIP-copper pairing, aiming to translate this technology into human applications. Collaborations with biotech firms focused on radiopharmaceutical development are facilitating the swift advancement of RIP-based therapeutics toward regulatory approval and clinical integration.

This research not only enriches the chemical biology of drug delivery but also redefines the pharmaceutical landscape by emphasizing the kinetic dimension of drug retention within tumors. By physically anchoring drugs to malignant cells, this approach mitigates premature drug dispersal, enhances therapeutic window, and curtails adverse effects. Michael Evans, a leading investigator in the study, underlines that maximizing tumor-specific drug delivery while sparing healthy tissues holds the promise of safer, more effective therapies.

The multidisciplinary team behind this technology, including experts from the University of California San Francisco, integrates expertise in peptide chemistry, enzymology, and oncology. Their meticulous design and characterization of RIPs exemplify the confluence of chemical innovation and clinical aspiration, establishing a platform adaptable to a range of oncological agents and diagnostic isotopes.

Funding from entities such as the Advanced Research Projects Agency for Health and the National Institutes of Health has been instrumental in propelling this research. The support underscores the growing recognition of targeted drug retention technologies as pivotal elements in the future of precision cancer medicine. Furthermore, some of the authors have spun out a company, TheraPaint, Inc., to accelerate the development of RIP-based radiopharmaceuticals for cancer theranostics.

Overall, this innovative molecular grappling hook strategy illuminates a promising frontier in oncological therapeutics. By harnessing biochemically triggered conformational changes to gain a physical foothold on cancer cell membranes, the approach offers a sophisticated solution to persistent challenges in drug delivery. As the field eagerly anticipates clinical validation, the technology exemplifies how molecular engineering can reconcile efficacy and safety in cancer treatment.

Subject of Research: Molecular drug delivery systems for cancer treatment
Article Title: Molecular grappling hooks improve cancer drug targeting and effectiveness
News Publication Date: 13-May-2026
Web References: http://pubs.acs.org/doi/abs/10.1021/acscentsci.6c00185
References: DOI: 10.1021/acscentsci.6c00185
Image Credits: Adapted from ACS Central Science 2026, DOI: 10.1021/acscentsci.6c00185

Keywords:
Chemistry, Cancer, Tumor cells, Peptides

Traditional drug design has predominantly relied on optimizing molecules to passively diffuse across cell membranes, a process largely dictated by Lipinski’s ‘Rule of 5’, which sets a molecular weight threshold of 500 daltons for optimal absorption. PROTACs, often exceeding 1,000 daltons, fall well above this limit, presenting a formidable barrier for effective cellular entry. The new technique exploits a naturally occurring protein called CD36, which is abundantly expressed on the surface of various cell types, including those in the intestine, skin, lungs, eyes, and certain brain cells. CD36 functions as a receptor facilitating the uptake of various molecules via endocytosis, a process by which cells internalize substances by engulfing them in vesicles.

By chemically engineering PROTAC molecules to actively engage the CD36 receptor, scientists have developed a strategy they term chemical endocytic medicinal chemistry (CEMC). This innovative approach turns the passive absorption paradigm on its head by harnessing the cell’s own uptake machinery to swallow large molecular drugs effectively. The results are striking: CD36-mediated delivery resulted in a 7.7 to 22.3-fold increase in intracellular drug concentration within cancer cells, leading to an up to 23-fold enhancement in therapeutic potency as demonstrated in rigorous preclinical studies published in the journal Cell.

The mouse model data reveal not only improved drug uptake but also a corresponding augmentation in tumor suppression without compromising the drug’s solubility or stability—two critical parameters for successful clinical application. This finding dispels previous concerns that enhancing cellular internalization might destabilize these large molecules or reduce their bioavailability. Instead, the CEMC strategy maintains these essential properties while ensuring that the active drug reaches its intracellular targets with unprecedented efficiency.

This advancement is particularly significant for the class of bRo5 molecules, which break the traditional ‘Rule of 5’ restrictions in medicinal chemistry and include various therapeutic agents beyond just PROTACs. PROTACs stand apart as unique targeted cancer therapies that work not by inhibiting enzymatic functions but by catalyzing the degradation of pathogenic proteins, effectively removing them from the cellular environment. This mode of action holds immense promise in combating drug resistance, a major challenge in oncology, as resistant tumors often evolve mechanisms to bypass enzymatic inhibitors but remain susceptible to protein degradation strategies.

The implications of CD36-mediated endocytosis extend well beyond oncology. While current attention is focused on PROTACs targeting cancer and neurodegenerative diseases like Parkinson’s disease, the underlying methodology could be universally applicable to many large, structurally complex therapeutic molecules previously deemed pharmacologically intractable. By opening the door to efficient intracellular delivery of these drugs, the study fosters new avenues for treating a variety of conditions that hinge on modulating protein expression or function inside cells.

Leading the charge to uncover CD36 as a key facilitator of drug internalization, Dr. Hong-yu Li from the University of Texas Health Science Center emphasized the paradigm shift heralded by this discovery. For decades, the scientific consensus held that molecules of this size could not cross membranes readily since the concept of endocytic uptake of chemically designed compounds was largely unexplored. The identification of CD36 as a receptor exploitable for drug entry has unlocked a previously inaccessible dimension of pharmacology, enabling researchers to optimize drug structures for receptor-mediated internalization rather than solely relying on membrane permeability.

The robustness of the findings is underscored by independent replication across the collaborative teams, including the work led by Dr. Zhiqiang Qin at the University of Arkansas Medical Sciences. Their collective research efforts confirm that this approach yields reproducible and significant improvements in drug performance, providing a strong foundation for the next phase of translational research and clinical development.

Despite the promising data, the authors caution that further extensive evaluations in clinical trials are required before CD36-mediated drug delivery can be widely implemented in patient care. These studies must ascertain the safety, efficacy, and pharmacokinetics in humans, as well as investigate possible off-target effects or immune responses arising from receptor engagement. Nevertheless, the prospect of converting previously ‘undruggable’ large molecules into viable therapeutics represents a transformative leap for drug discovery.

Beyond the mechanistic insight, this breakthrough also shifts the drug development focus from passive molecular optimization to harnessing intricate cellular processes. It paves the way for a future in which medicinal chemistry can systematically exploit receptor-mediated endocytosis, moving toward a more sophisticated and biologically integrated approach to drug design. Such strategies could herald a new era in which the molecular size and complexity of therapeutic agents are no longer insurmountable obstacles but deliberately tailored features to enhance receptor engagement and drug delivery.

Conventional cancer treatments, such as kinase inhibitors, target specific enzymatic activities within cancer cells but often fail to eliminate the proteins themselves, leaving residual functions that contribute to disease progression and therapeutic resistance. By contrast, PROTACs promote complete degradation of these proteins, thereby delivering a more comprehensive therapeutic effect and reducing the likelihood of resistance. By leveraging CD36 to increase the intracellular concentration of PROTAC drugs, this approach amplifies their ability to dismantle oncogenic proteins and impede tumor growth more effectively.

Eight oral PROTAC candidates are actively undergoing clinical trials, including a Phase 3 study evaluating one agent designed to degrade estrogen receptors in breast cancer. The ability to enhance PROTAC bioavailability through CD36 engagement could tremendously impact these ongoing trials and future drug pipelines, potentially increasing the success rates and broadening the applicability of protein-degrading therapies.

The multidisciplinary collaboration and generous support from major funding bodies such as the National Institutes of Health and the Cancer Prevention and Research Institute of Texas highlight the importance and high interest in developing next-generation treatment modalities. Together, these efforts signify a pivotal advancement with far-reaching consequences for medicinal chemistry, oncology, and beyond.

Ultimately, chemical endocytic medicinal chemistry stands as a beacon of innovation, propelling the drug discovery field toward overcoming size limitations and expanding the therapeutic toolbox with highly potent, large molecule drugs that can be efficiently internalized by cells. As research advances, this novel strategy holds the potential to not only improve patient outcomes in cancer but also transform treatment paradigms across various diseases driven by pathogenic proteins.

Subject of Research: Cells

Article Title: CD-36-mediated endocytosis of proteolysis-targeting chimeras

News Publication Date: April 17, 2025

Web References:
https://doi.org/10.1016/j.cell.2025.03.036

References:
Lin, H.-K., Li, H.-Y., Qin, Z., et al. "CD-36-mediated endocytosis of proteolysis-targeting chimeras," Cell, April 17, 2025.

Image Credits:
Duke University School of Medicine

Keywords:
Cancer medication, Surface proteins, Drug design, Cancer cells, Drug resistance, Drug therapy